对于对4mg多沙唑嗪控释片治疗良性前列腺增生反应不足的患者，测定8mg多沙唑嗪控释片的治疗效果。

Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia.

作者信息

Keten Tanju, Aslan Yilmaz, Balci Melih, Tuncel Altug, Bilgin Ovunc, Dilmen Cem, Ozdemir Umit, Yahsi Sedat, Guzel Ozer, Atan Ali

机构信息

Third Department of Urology, Ministry of Health, Ankara Numune Research and Training Hospital, Ankara, Turkey.

出版信息

Urology. 2015 Jan;85(1):189-94. doi: 10.1016/j.urology.2014.10.004.

DOI:10.1016/j.urology.2014.10.004

PMID:25530384

Abstract

OBJECTIVE

To compare the efficacy of 4 mg and 8 mg doxazosin XL treatments in patients with benign prostatic hyperplasia-related lower urinary tract symptoms and determine the efficiency of 8 mg in those patients with inadequate response to 4 mg.

METHODS

A total of 162 patients were included in this study. Of the patients, 108 were randomized to receive 4 mg doxazosin XL (group 1), and 54 were randomized to receive 8 mg (group 2) treatments. After 1 month of treatment, 31 patients in group 1 whose quality of life (QoL) score was unchanged or had deteriorated were switched to 8 mg doxazosin XL treatment (group 1b).

RESULTS

The mean age was 59.8 years. After 1 month of treatment, the mean alteration in the International Prostate Symptom Score was 3.9 and 5.2 (P = .028), for the maximum urinary flow rate (Q(max)), it was 3.0 and 3.6 mL/s (P = .206), and for the QoL score it was 1.3 and 1.7 (P = .038) in groups 1 and 2, respectively. For group 1b, during the period in which the patients were receiving 4 and 8 mg doxazosin XL treatments; the International Prostate Symptom Score changes were 1.3 and 3.6 (P <.001), the Q(max) changes were 1.6 and 3.2 mL/s (P <.019), and the QoL changes were 0.4 and 1.8 (P <.001) in groups 1 and 2, respectively.

CONCLUSION

With no changes in side effects, 8 mg doxazosin XL treatment is an efficient choice for patients who did not have an adequate response to 4 mg doxazosin XL treatment.

摘要

目的

比较4毫克和8毫克多沙唑嗪控释片治疗良性前列腺增生相关下尿路症状患者的疗效，并确定8毫克剂量对4毫克剂量治疗反应不足的患者的有效性。

方法

本研究共纳入162例患者。其中，108例患者随机接受4毫克多沙唑嗪控释片治疗（第1组），54例患者随机接受8毫克治疗（第2组）。治疗1个月后，第1组中生活质量（QoL）评分未改变或恶化的31例患者改用8毫克多沙唑嗪控释片治疗（第1b组）。

结果

平均年龄为59.8岁。治疗1个月后，第1组和第2组的国际前列腺症状评分平均变化分别为3.9和5.2（P = 0.028），最大尿流率（Q(max)）分别为3.0和3.6毫升/秒（P = 0.206），QoL评分分别为1.3和1.7（P = 0.038）。对于第1b组，在患者接受4毫克和8毫克多沙唑嗪控释片治疗期间，第1组和第2组的国际前列腺症状评分变化分别为1.3和3.6（P <0.001），Q(max)变化分别为1.6和3.2毫升/秒（P <0.019），QoL变化分别为0.4和1.8（P <0.001）。